Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conceptus' STOP

This article was originally published in The Gray Sheet

Executive Summary

Selective tubal occlusion procedure system premarket approval application submission to FDA is slated for the third quarter of 2002. Bilateral placement of the non-surgical permanent contraception device has been achieved in more than 400 patients in a clinical study, the firm reports Jan. 3. Trial protocol requires 12 months of follow-up after each patient begins to rely exclusively on the device for contraception, which occurs three months following the placement procedure
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT014317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel